JS212 alone or combined in triple-negative breast cancer that returned or spread
Tests JS212, alone or combined, in adults with returned or spread triple-negative breast cancer.
Plain-language title generated from the registry record
Registry title: A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
Key facts
- Where
- Baoding, Beijing, Changchun, Changde, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Jinan, Jining, Lanzhou, Mianyang, Nanchang, Nanjing, Qingdao, Shenyang, Taiyuan, Weifang, Wuhan, Yinchuan, and Zhengzhou, ChinaSee the 31 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07876557, who can take part
Where in China
- Affiliated Hospital of Hebei UniversityBaoding, ChinaNot yet recruiting
- Peking University People's HospitalBeijing, ChinaTaking people
- Peking University Shougang HospitalBeijing, ChinaNot yet recruiting
- The Fifth medical center of Chinese PLA General HospitalBeijing, ChinaNot yet recruiting
- Jilin Provincial Cancer HospitalChangchun, ChinaNot yet recruiting
- The First Hospital of Jilin UniversityChangchun, ChinaNot yet recruiting
- The First People's Hospital of Changde CityChangde, ChinaNot yet recruiting
- Hunan Cancer HospitalChangsha, ChinaNot yet recruiting
- Sichuan Provincial People's HospitalChengdu, ChinaNot yet recruiting
- Fujian Cancer HospitalFuzhou, ChinaNot yet recruiting
- Guangdong General HospitalGuangzhou, ChinaNot yet recruiting
- Sun Yat-sen University Cancer CenterGuangzhou, ChinaNot yet recruiting
- The Affiliated Cancer Hospital of Guizhou Medical University City: GuiyangGuiyang, ChinaNot yet recruiting
- The Affiliated Hospital of Guizhou Medical UniversityGuiyang, ChinaNot yet recruiting
- Harbin Medical University Cancer HospitalHarbin, ChinaNot yet recruiting
- Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute, Shandong Cancer Hospital)Jinan, ChinaNot yet recruiting
- Affiliated Hospital of Jining Medical UniversityJining, ChinaNot yet recruiting
- The First Hospital of Lanzhou UniversityLanzhou, ChinaNot yet recruiting
- Mianyang Central HospitalMianyang, ChinaNot yet recruiting
- Nanchang People's HospitalNanchang, ChinaNot yet recruiting
- Jiangsu Province HospitalNanjing, ChinaNot yet recruiting
- The Affiliated Hospital of Qingdao UniversityQingdao, ChinaNot yet recruiting
- Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital & Institute)Shenyang, ChinaNot yet recruiting
- Introduction to the First Affiliated Hospital of China Medical UniversityShenyang, ChinaNot yet recruiting
- Shengjing Hospital Of China Medical UniversityShenyang, ChinaNot yet recruiting
- Shanxi Cancer hospitalTaiyuan, ChinaNot yet recruiting
- Weifang People's HospitalWeifang, ChinaNot yet recruiting
- Hubei Cancer HospitalWuhan, ChinaNot yet recruiting
- General Hospital of Ningxia Medical UniversityYinchuan, ChinaNot yet recruiting
- Henan Cancer HospitalZhengzhou, ChinaNot yet recruiting
- The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Junshi Bioscience Co., Ltd.
- Trial code
- NCT07876557
- Record updated
- 5 November 2026
- Original description
This is an phase II study to prelininarily evaluate the efficacy and safety of JS212 mono therapy or combination therapy in patients with recurrent or metastatic TNBC.Read full original descriptionShow less
A Phase II Study of JS212 Monotherapy or Combination Therapy With JS207 or JS001 in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
This is an phase II study to prelininarily evaluate the efficacy and safety of JS212 mono therapy or combination therapy in patients with recurrent or metastatic TNBC.
Inclusion: Male or female age 18-70 years old; Voluntary participation in clinical study; Histologically confirmed unresectable, locally advanced or metastatic triple-negative breast cancer(absence of HER2, ER, and PR expression); No prior systemic antitumor therapy for locally advanced or Metastatic TNBC（cohort expansion period); only one line of prior systemetic treatment for locally advanced or metastatic TNBC; Adequate organ function; ECOG performance status of 0 or 1; Life expectancy 12 weeks; Measurable disease, as defined by RECIST v1.1.
Exclusion: Active autoimmune diseases requiring systemic treatmen within 2 years prior to the first dose; History of interstitial lung disease or previous Noninfectious pneumonitis treated with corticosteroids, or evidence of active Pneumonia in radiology on screening period; Serious infection (CTCAE 6.0 Grade>2) within 28 days prior to the first dose of study drug; Tumor encasement of important vessels or significant necrosis and cavitation that may cause a risk of hemorrhage; History of significant bleeding tendency or severe coagulation disorder; Uncontrolled hypertension; History of immunodeficiency. Presence of active tuberculosis, hepatitis B, or hepatitis C; Severe cardiovascular disease; History of another malignancy within 5 years before the first dose of study drug; Not suitable to receive study treatment for other conditions as per investigator; Previous treatment of any anti-VRGF drugs targeting VEGF (part 1) or ADC drugs targeting EGFR and/or HER3; Untreated or active central nervous system (CNS) metastases; Uncontrolled pleural effusion, pericardial effusion or ascites.